NICE Endorses Natalizumab RRMS Treatment Expans...

By João L. Carapinha

January 9, 2026

NICE Expands Access to Natalizumab RRMS Treatment for Highly Active Cases The National Institute for Health and Care Excellence (NICE) has issued final draft ...
Advancing EU Health Technology Assessment: Key Priorities in the HTACG Draft ...
Biomanufacturing Excellence Act: Strengthening U.S. Biopharmaceutical Manufac...
Medicare Drug Price Negotiations: Major Savings for Seniors on Cancer and Chr...
Rethinking HEOR Market Access Integration: A Call for Early Engagement Before...
Navigating Targeted Therapy Access: Innovations and Challenges in High-Cost T...
Koselugo EU Approval: A Milestone in Treating Plexiform Neurofibromas for Adu...
Challenging the Narrative: Pharmaceutical Innovation Funding and Its Complex ...
NICE Endorses Darolutamide Prostate Cancer Treatment for Improved Patient Access
Pfizer Trump Drug Prices: A Landmark Deal for Affordable Medications
Sanofi Insulin Savings: Your Comprehensive Guide for 2025
The Market Dynamics of Track One Patent Strategy in Pharmaceuticals
Biosimilars Market Trends 2025: Understanding Erosion and Growth